Avilar Therapeutics

Avilar Therapeutics

  • Founded: 2020
  • Location: Waltham, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Autoimmune diseases
  • Drug types: IMM, NEU
  • Lead product: Undisclosed
  • Product link: https://avilar-tx.com/applications/
  • Funding: $15M Seed Feb 2023; $60M Seed Nov 2021
  • Investors: RA Capital Management, Sanofi Ventures, Medical Excellence Capital (MEC), Astellas Venture Management



job board

Short description:

Extracellular Targeted Protein Degradation

Drug notes:

Additional undisclosed programs RD neurological conditions, undisclosed

Long description:

Avilar Therapeutics is developing methods to degrade extracellular proteins. More than 35% of human proteins are located outside the cell and many have a clearly defined role in the pathogenesis of human diseases. Avilar is developing novel degraders of extracellular proteins as future medicines for the treatment of multiple serious diseases. Avilar’s new class of degraders harness ASGPR receptors that play a key role in the natural process through which endogenous proteins are internalized and degraded by hepatocytes. The degraders are bifunctional molecules that bind both ASGPR and a disease-causing extracellular protein. Using an X-ray structure guided approach, Avilar is discovering a library of bifunctional, high affinity molecules to target a wide range of extracellular proteins.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com